Recent Research Analysts’ Ratings Changes for Pacific Biosciences of California (PACB)

A number of research firms have changed their ratings and price targets for Pacific Biosciences of California (NASDAQ: PACB):

• 11/9/2026 – Pacific Biosciences of California had its price target lowered by UBS Group from $3.05 to $2.70. They now have a “neutral” rating on the stock.
• 11/7/2026 – Pacific Biosciences of California was upgraded by Wall Street Zen from “sell” to “hold”.
• 11/5/2026 – Pacific Biosciences of California had its price target raised by Barclays from $1.25 to $2.00. They now have an “underweight” rating on the stock.
• 11/5/2026 – Pacific Biosciences of California had its “neutral” rating reaffirmed by Piper Sandler. They now have a $3.00 price target on the stock, up from $2.00.
• 10/13/2026 – Pacific Biosciences of California was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/28/2026 – Pacific Biosciences of California was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Pacific Biosciences of California Stock Performance

Pacific Biosciences of California stock opened at $2.09 on Thursday. The company has a 50 day moving average price of $1.98 and a 200 day moving average price of $1.61. Pacific Biosciences of California, Inc. has a 52 week low of $1.07 and a 52 week high of $3.43. The firm has a market capitalization of $654.02 million, a price-to-earnings ratio of -4.98 and a beta of 2.21.

Pacific Biosciences of California (NASDAQ:PACB) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. The company had revenue of $40.56 million for the quarter, compared to the consensus estimate of $39.31 million. Pacific Biosciences of California had a negative net margin of 81.31% and a negative return on equity of 5,752.12%. Equities analysts forecast that Pacific Biosciences of California, Inc. will post -0.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Mark Van Oene sold 26,911 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1.13, for a total transaction of $30,409.43. Following the completion of the sale, the insider directly owned 2,705,853 shares in the company, valued at approximately $3,057,613.89. This trade represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James Gibson, II sold 661,815 shares of Pacific Biosciences of California stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total transaction of $2,058,244.65. Following the sale, the insider directly owned 1,083,848 shares of the company’s stock, valued at $3,370,767.28. This trade represents a 37.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is owned by corporate insiders.

Pacific Biosciences of California, or PacBio, develops and sells DNA sequencing systems and related products for life science research and clinical applications. The company is known for its single-molecule real-time (SMRT) sequencing technology, which produces long reads that can help researchers study complex regions of the genome and identify genetic variations. Its portfolio includes HiFi sequencing systems such as the Revio and Vega platforms, along with instruments, consumables, software and services used to prepare, sequence and analyze genetic samples.